Cardiol Therapeutics Inc. (CRDL)
| Market Cap | 156.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.67M |
| Shares Out | 111.87M |
| EPS (ttm) | -0.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 405,423 |
| Open | 1.410 |
| Previous Close | 1.400 |
| Day's Range | 1.345 - 1.420 |
| 52-Week Range | 0.880 - 1.710 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+520.44%) |
| Earnings Date | May 13, 2026 |
About CRDL
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical develop... [Read more]
Analyst Forecast
According to 2 analysts, the average rating for CRDL stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 520.44% from the latest price.
News
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Lang...
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the dev...
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026. Reported positive Phase II ARCHER data...
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the ...
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the ...
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the d...
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the d...
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the d...
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients. Activation of additional top-tier clinical sites in Europe and...
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... • news
Cardiol Therapeutics Inc To Present Phase II ARCHER Results Transcript
Cardiol Therapeutics Inc To Present Phase II ARCHER Results Transcript
Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News
Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual prop...
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis. Presentation to provide comprehensive findings from the ARCHER trial followin...
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHE...
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHE...
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing a...
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo. Reduction in ECV was associated with imp...
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in m...
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti...
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti...
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: C...